
GENFIT
GNFT | XPAR
Overview
Corporate Details
- ISIN(s):
- FR0004163111 (+2 more)
- LEI:
- 969500XPWN2DMZQA5X73
- Country:
- France
- Address:
- 885 AVENUE EUGENE AVINEE, 59120 LOOS
- Website:
- https://www.genfit.com
- Sector:
- Health Care
- Industry:
- Biotechnology
Description
GENFIT is a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases. GENFIT is a pioneer in the field of nuclear receptor-based drug discovery, with a rich history and strong scientific heritage spanning more than two decades. Today, GENFIT has a robust and diversified pipeline, using different compounds and technologies evaluated at different development stages and in different liver diseases. Leveraging its internal assets and in-house expertise, GENFIT’s R&D is focused on cholestatic diseases and Acute on Chronic Liver Failure (ACLF): two therapeutic areas with significant unmet medical needs. Currently, the ELATIVE™ Phase 3 clinical trial is evaluating elafibranor (elafibranor is an investigational compound that has not been reviewed nor been approved by a regulatory authority) in patients with Primary Biliary Cholangitis (PBC) following a successful Phase 2 clinical trial.
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
Date | Filing | Language | Size | Actions |
---|---|---|---|---|
2025-05-22 22:10 |
Earnings Release
GENFIT Reports First Quarter 2025 Financial Information
|
English | 163.4 KB | |
2025-05-22 22:10 |
Earnings Release
GENFIT : Information financière du premier trimestre 2025
|
French | 146.7 KB | |
2025-05-20 22:10 |
Regulatory News Service
GENFIT to receive a €26.5 million milestone payment following the approval of p…
|
English | 143.6 KB | |
2025-05-20 22:10 |
Regulatory News Service
GENFIT va recevoir un paiement d’étape de 26,5 millions d’euros à la suite de l…
|
French | 137.3 KB | |
2025-05-14 22:10 |
Sustainability Report
GENFIT: Publication of the 2025 Extra-Financial Performance Report (fiscal year…
|
English | 793.3 KB | |
2025-05-07 22:10 |
General Meeting Notice
GENFIT : Assemblée Générale Mixte du 17 juin 2025 — modalités de mise à disposi…
|
French | 129.1 KB | |
2025-05-07 22:10 |
General Meeting Notice
GENFIT Annual Combined General Meeting of June 17, 2025 — Availability of Prepa…
|
English | 135.6 KB | |
2025-05-05 07:30 |
Inside Information Statement
GENFIT présentera ses dernières avancées dans l'ACLF à l’EASL Congress 2025
|
French | 228.8 KB | |
2025-05-05 07:30 |
Regulatory News Service
GENFIT to Present Latest ACLF Research at EASL Congress 2025
|
English | 220.7 KB | |
2025-04-29 21:10 |
Report Publication Announcement
GENFIT : Mise à disposition du Document d’Enregistrement Universel 2024 et du R…
|
French | 516.5 KB | |
2025-04-29 21:10 |
Report Publication Announcement
GENFIT Announces Publication of the 2024 Universal Registration Document and th…
|
English | 648.6 KB | |
2025-04-29 12:14 |
Annual Report (ESEF)
Document d'Enregistrement Universel 2024
|
French | 10.4 MB | |
2025-04-28 22:10 |
Regulatory News Service
GENFIT : les données positives de la Phase 2 évaluant elafibranor dans la Chola…
|
French | 181.9 KB | |
2025-04-28 22:10 |
Inside Information Statement
GENFIT: positive late-breaking Phase 2 data for elafibranor in Primary Sclerosi…
|
English | 189.9 KB | |
2025-04-24 22:10 |
Earnings Release
GENFIT Reports Full-Year 2024 Financial Results and Provides Corporate Update
|
English | 282.4 KB |
Insider Transactions
Date | Insider Name | Position | Type | Shares | Value |
---|---|---|---|---|---|
2023-07-07 | N/A | Other | Buy | 5,300 | 19,488.10 EUR |
2023-07-06 | N/A | Other | Buy | 1,100 | 4,048.00 EUR |
2023-07-05 | N/A | Other | Buy | 10,000 | 37,061.00 EUR |
2023-07-03 | N/A | Other | Buy | 5,300 | 18,769.95 EUR |
Peer Companies
Company | Country | Ticker | View | |
---|---|---|---|---|
![]() |
1NKEMIA | Spain | IKM | |
![]() |
2cureX AB | Sweden | 2CUREX | |
![]() |
4SC AG | Germany | VSC | |
![]() |
Abera Bioscience AB | Sweden | ABERA | |
![]() |
ABIONYX Pharma | France | ABNX | |
|
Abliva | Sweden | ABLI | |
![]() |
AB Science | France | AB | |
![]() |
Acticor Biotech | France | ALACT | |
![]() |
Active Biotech | Sweden | ACTI | |
![]() |
AcuCort AB | Sweden | ACUC |